Condition
Endometrioid Carcinoma
Total Trials
5
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting2
Recruiting1
Withdrawn1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT02598219Phase 3Active Not Recruiting
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
NCT03875820Phase 1Active Not Recruiting
Phase I Trial of Defactinib and VS-6766.
NCT06549855Not ApplicableNot Yet Recruiting
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
NCT05080556Phase 2Recruiting
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
NCT01732432WithdrawnPrimary
Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
Showing all 5 trials